Short treatment for drug-resistant TB in people with diabetes
Part of Hormones & metabolism clinical trials.
This study tests a shorter treatment combination (using pretomanid) for people who have both diabetes and TB that is resistant to common drugs. It aims to see if this new short course works well and is safe for this group, potentially reducing treatment time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 12 years old and weigh at least 30 kilograms (about 66 pounds).
- You have pulmonary tuberculosis that does not respond to rifampicin (or to rifampicin and isoniazid).
- You have diabetes, either newly diagnosed or existing.
- If you are a woman who could become pregnant, you must not be pregnant, agree to a pregnancy test, and use effective birth control during and for 3 months after treatment.
- If you are a man, you must use condoms or another reliable method to prevent pregnancy in your partner during and for 3 months after treatment.
- You have not previously used bedaquiline or delamanid for more than 28 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a shorter treatment for drug-resistant tuberculosis (TB) using a medicine called pretomanid. It aims to see if a shorter course of treatment can effectively cure TB that doesn't respond to a standard drug called rifampicin, reducing treatment time for patients.
This study tests a shorter treatment for a type of TB that is resistant to rifampicin (a common TB medicine) but still sensitive to isoniazid. It aims to see if this shorter regimen is as effective as the current longer one, potentially making treatment less burdensome for patients.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This study tests new combinations of drugs for treating pulmonary tuberculosis (TB). The goal is to find more effective and safer treatments than the current standard.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
This trial tests a shorter treatment for tuberculosis (TB) using a combination of three medicines: bedaquiline, moxifloxacin, and pyrazinamide. If you have TB in your lungs, this could be a way to treat it more quickly than the standard longer course.
Hear when a new Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.